This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Burzynski, S. R. Articles by Burzynski, B. Search for Related Content PubMed PubMed Citation Articles by Burzynski, S. R. Articles by Burzynski, B. Social Bookmarking                         What's this?

Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma

Department of Internal Medicine, Burzynski Clinic, Houston, Texas, srb{at}burzynskiclinic.com

Tomasz J. Janicki, MD

Department of Medical Documentation, Burzynski Clinic, Houston, Texas

Robert A. Weaver, MD

Department of Internal Medicine, Burzynski Clinic, Houston, Texas

Barbara Burzynski, MD

Department of Pharmacy, Burzynski Clinic, Houston, Texas

Background: Brainstem glioma carries the worst prognosis of all malignancies of the brain. Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years. Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG). The objective of this report is to summarize the outcome of patients with HBSG treated with antineoplastons in 4 phase 2 trials. Patients: The following group of 18 patients was evaluable: 4 patients with glioblastomas and 14 patients with anaplastic HBSG. Fourteen patients had diffuse intrinsic tumors. Twelve patients suffered from recurrence, and 6 patients did not have radiation therapy or chemotherapy. Methods: Antineoplastons, which consist of antineoplaston A10 (A10I) and AS2-1 injections, were given in escalating doses by intravenous injections. The median duration of antineoplaston administration was 5 months, and the average dosage of A10I was 9.22 g/kg/d and of AS2-1 was 0.31 g/kg/d. Responses were assessed by gadolinium-enhanced magnetic resonance imaging and positron emission tomography. Results: The overall survival at 2 and 5 years was 39% and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma. Progression-free survival at 6 months was 39%. Complete response was achieved in 11%, partial response in 11%, stable disease in 39%, and progressive disease in 39% of patients. Antineoplastons were tolerated very well with 1 case of grade 4 toxicity (reversible anemia). Conclusion: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.

Key Words: brainstem glioma • glioblastoma • GBM • astrocytoma • glioma • brain tumor • antineoplastons • ANP

Integrative Cancer Therapies, Vol. 5, No. 1, 40-47 (2006)
DOI: 10.1177/1534735405285380


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Munshi, L. H. Ni, and M. S. Tiwana Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls Jpn. J. Clin. Oncol., August 5, 2008; (2008) hyn066v1. [Abstract] [Full Text] [PDF]